Physician profile
Anna K Imperato
NPI 1104880780
$422,329.34
in general payments reported to CMS, 2019-2025
53 companies · $33K in 2025
The $33K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $45K · 2021: $27K · 2022: $58K · 2023: $49K · 2024: $60K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Food and Beverage: $17K · Travel and Lodging: $14K · Consulting Fee: $7,010 · Education: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,852.59 |
| Food and Beverage | $16,637.81 |
| Travel and Lodging | $13,560.69 |
| Consulting Fee | $7,010.00 |
| Education | $615.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $118,308.41 | 2019-2025 | Taltz |
| Mallinckrodt Hospital Products INC. | $74,917.50 | 2020-2025 | Acthar |
| Celgene Corporation | $47,102.53 | 2019 | |
| Amgen INC. | $45,714.45 | 2019-2025 | Otezla, Tavneos, Enbrel |
| Novartis Pharmaceuticals Corporation | $42,180.56 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $22,114.48 | 2024 | Arcalyst |
| Janssen Biotech, INC. | $21,246.77 | 2019-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Enterprises LLC | $17,586.77 | 2019 | |
| Abbvie INC. | $7,756.59 | 2019-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $6,232.13 | 2021-2023 | Arcalyst |
| Genentech USA, INC. | $4,304.22 | 2019-2025 | Actemra, Rituxan |
| Eli Lilly and Company | $3,053.12 | 2019-2022 | |
| Horizon Therapeutics Plc | $2,672.58 | 2019-2023 | Krystexxa |
| Pfizer INC. | $1,737.13 | 2019-2025 | |
| Radius Health, INC. | $1,159.84 | 2019-2025 | Tymlos |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $1,122.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $578.64 | 2019-2025 | Benlysta |
| Ucb, INC. | $557.98 | 2019-2025 | Bimzelx, Cimzia |
| Hikma Pharmaceuticals USA | $532.50 | 2019-2023 | Mitigare |
| E.R. Squibb & Sons, L.L.C. | $479.46 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $470.40 | 2021-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $365.77 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.91 | 2020-2025 | Ofev, Cyltezo |
| Alexion Pharmaceuticals, INC. | $228.56 | 2021-2025 | Strensiq |
| Octapharma USA, INC. | $157.92 | 2024-2025 | Octagam Immune Globulin (Human) |
| Depuy Synthes Sales INC. | $146.31 | 2019-2024 | Orthovisc |
| Grifols USA, LLC | $108.08 | 2022-2025 | Gamunex-C |
| Scilex Pharmaceuticals INC. | $104.29 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $101.04 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $100.97 | 2021-2023 | Euflexxa |
| Actelion Pharmaceuticals US, INC. | $94.42 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $86.20 | 2019 | |
| Medexus Pharma, INC. | $78.67 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $62.22 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $61.71 | 2019 | |
| Bioventus LLC | $52.01 | 2024 | Durolane |
| Merck Sharp & Dohme LLC | $47.50 | 2019 | |
| Genzyme Corporation | $43.40 | 2021-2025 | |
| Gilead Sciences, INC. | $39.99 | 2020 | |
| Genentech, INC. | $39.95 | 2019 | |
| Dova Pharmaceuticals | $37.54 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $36.77 | 2019-2021 | |
| Sandoz INC. | $34.78 | 2023-2024 | Hyrimoz |
| Janssen Scientific Affairs, LLC | $31.52 | 2021 | |
| Sun Pharmaceutical Industries INC. | $31.33 | 2025 | |
| Alvogen INC | $23.33 | 2023 | Teriparatide |
| Argenx US, INC. | $21.67 | 2024 | Vyvgart |
| Antares Pharma, INC. | $21.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.87 | 2020 | |
| Bio Products Laboratory USA, INC. | $18.02 | 2023 | Gammaplex, Coagadex |
| Eyevance Pharmaceuticals LLC | $16.10 | 2021 | |
| Daiichi Sankyo INC. | $14.44 | 2020 | |
| Csl Behring | $14.17 | 2024 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Imperato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.